Strategic report Review of our business Shire delivers record full-year revenue with key growth contributions from all therapeuticareas.
Jeff Poulton Chief Financial Officer increased discounts, which reduce Shires in-licensing and acquisition efforts Overview revenue, due to the population of baby are focused on products in specialist The Company has grown both organically boomers covered under Medicare, markets with strong intellectual property and through acquisition, completing a specifically those beneficiaries receiving protection or other forms of market series of major transactions that have drug cost offset through the Medicare exclusivity and global rights.
Shire believes brought therapeutic, geographic and Part D Coverage Gap the Donut Hole : that a carefully selected and balanced pipeline growth and diversification.
The portfolio of products with strategically Company will continue to conduct its own increasing challenges from third-party aligned and relatively small-scale sales research and development, focused on rare payers for products to have forces will deliver strong results.
diseases, as well as evaluate companies, demonstrable clinical benefit, with pricing products and pipeline opportunities that Company revenues, expenditures and and reimbursement approval becoming offer a strategic fit and have the potential netassets are attributable to the R&D, increasingly linked to a products clinical todeliver value to all of the Companys manufacture, sale and distribution of effectiveness and impact on overall costs stakeholders: patients, physicians, policy pharmaceutical products within one of patient care: makers, payers, partners, investors reportable segment.
increased R&D costs, because earns royalties where Shire has outdevelopment programs are typically licensed products to third-parties which The Companys purpose is to enable larger and take longer to get approval are recorded as royalty revenues.
people with life-altering conditions to lead from regulators: better lives.
The Company will execute on Revenues are derived primarily from two its purpose through its strategy and challenges to existing patents from sources sales of the Companys own business model.
For further details of generic manufacturers: products and royalties: Shires strategy and business model, refer governments and healthcare systems to pages 12 and 14.
95.5percent 2015: 95.0percent of total favoring earlier entry of low cost generic revenues are derived from Product sales: Through deep understanding of patients drugs: and and needs, the Company is able to: higher marketing costs, due to increased 4.5percent 2015: 5.0percent of total serve patients with high unmet needs in competition for market share.
revenues are derived from royalties.
select, commercially attractive specialty Shires strategy has been developed to therapeutic areas: The markets in which the Company address these industry-wide competitive conducts its business are intensely drive optimum performance of its pressures.
This strategy has resulted in a competitive and highly regulated.
marketed products to serve patients series of initiatives in the following areas: today: and The healthcare industry is also experiencing: build its pipeline of innovative specialist treatments through both R&D and pressure from governments and Corporate Development activities to healthcare providers to keep prices enable the Company to serve patients in lowwhile increasing access to drugs: the future.
Shire Annual Report 2016 43 Other information Financial statements Governance Strategic report Review of our business continued The acquisition of NPS Pharma added Markets R&D global rights to an innovative product Shires current portfolio of approved Shires R&D efforts are focused on six portfolio with multiple growth catalysts, products spans seven key therapeutic therapeutic areas: Neuroscience, including GATTEX REVESTIVE and areas TAs : Hematology, Genetic Ophthalmology, Hematology, Oncology, NATPARA.
The acquisition of Meritage Diseases HAE LSD, Neuroscience, Immunology, GI Metabolic Endocrinology Pharma provided global rights to SHP621, Immunology, Internal Medicine, Oncology Diseases.
Shire concentrates its resources a Phase 3 ready asset for the treatment of and Ophthalmology.
In addition, Shire has a on obtaining regulatory approval for later adolescents and adults with EoE, a rare, number of marketed products for other TAs stage pipeline products within these chronic inflammatory GI disease.
This from which it generates Product sales or therapeutic areas and focuses its early builds upon the Companys rare disease royalties.
In 2016, the contribution of each stage research activities in rare diseases.
and GI commercial infrastructure and TA to overall Product sales was as follows: Evidence of the successful progression of expertise.
With the acquisition of Foresight the late stage pipeline can be seen in the Product Shire acquired the global rights to SHP640 granting of approval and associated sales Percentage topical ophthalmic drops combining $M % launches of the Companys products over 0.6percent povidone iodine PVP-I and the last three years.
In this time, several Hematology 2,240.8 20.6 0.1percent dexamethasone, a potential products have received regulatory approval Genetic Disease 2,698.0 24.8 therapy in late-stage development for including: in the U. S. XIIDRA and CUVITRU thetreatment of infectious conjunctivitis, Neuroscience 2,490.5 22.9 in 2016, VONVENDI, ADYNOVATE, anocular surface condition commonly Immunology 1,516.1 13.9 NATPARA and VYVANSE for BED in 2015, referred to as pink eye.
This acquisition Internal Medicine 1,755.5 16.1 HYQVIA and OBIZUR in 2014: in the EU, hasa clear strategic fitwith XIIDRA, Oncology 130.5 1.2 ONIVYDE and CUVITRU in 2016, whichis approved in the U. S. for the Ophthalmology 54.4 0.5 ELVANSE TYVENSE for adults, INTUNIV treatment of the signs and symptoms of for children and adolescents and OBIZUR 10,885.8 100.0 dryeye disease, and further demonstrates in 2015.
Shires commitment to building a leadership Shire has grown in part through acquisition position in ophthalmics.
Shires management reviews direct costs which has brought therapeutic, geographic for all R&D projects by development phase.
In 2016, Shire derived 32percent and pipeline growth and diversification.
2015:27percent of Product sales from Shires R&D costs in 2016 and 2015 include The acquisition of Baxalta in 2016 added outside of the U. S. Shire has ongoing expense on programs in all stages of the Hematology, Immunology and commercialization and late-stage development.
The following table provides Oncology franchises and enabled Shire to development activities, which are an analysis of the Companys direct R&D become the global leader in rare diseases expectedto further supplement the spend categorized by development stage, and highly specialized conditions.
diversification of revenues in the future, based upon the development stage of each including the following: program as of December 31, 2016 and 2015: The acquisition of Dyax in January 2016, with their lead pipeline product, SHP643, continued launch of INTUNIV, 2016 2015 and marketed product KALBITOR, expanded REVESTIVE and ONIVYDE across As of December 31 $M $M and extended Shires industry-leading HAE Europe: Early stage programs 325.7 177.2 portfolio FIRAZYR and CINRYZE.
review of MAAs for NATPAR and Late stage programs 291.1 225.5 In July 2016, Shire licensed the global rights ADYNOVI in the EU: Currently marketed to all indications for SHP647 from Pfizer Inc. products 238.1 178.5 review of NDA for SHP465 in U. S. : SHP647 is an investigational biologic being Total 854.9 581.2 evaluated for the treatment of  of CALPEG NDA for ALL severe inflammatory bowel disease.
S. : Early stage programs include preclinical In 2015, Shire acquired NPS Pharma, and research programs.
In addition to the submission of VONVENDI MAA Meritage Pharma and Foresight.
above, the Company recorded R&D inEurope: employee costs of $431.9 million in 2016 headline data from registration studies 2015: $302.9 million and other indirect forSHP643: and R&D costs of $153.0 million 2015: $679.9million, comprising mainly geographic expansion of XIIDRA with depreciation and milestone expense submissions in other key markets.
For a discussion of the Companys current development projects see pages 20 to 21.
44 Shire Annual Report 2016 Patents and Market Exclusivity On June 3, 2016, Shire acquired all of the Royalties and other revenues increased The loss or expiration of patent protection outstanding common stock of Baxalta.
by 61percent to $511 million, as the or regulatory exclusivity with respect to any Baxalta was a global biopharmaceutical second half of 2016 benefited from of the Companys major products could company, focused on developing, additional revenue following the have a material adverse effect on the manufacturing and commercializing acquisition of Baxalta, primarily related Companys revenues, financial condition therapies for orphan diseases and tocontract manufacturing activities.
and results of operations, as generic or underserved conditions in hematology, Operating results biosimilar products may enter the market.
Baxalta Operating income decreased 32percent Companies selling generic products often added a number of commercially approved to $963 million 2015: $1,420 million, do not need to complete extensive clinical products and enhanced Shires existing primarily due to the impact of the studies when they seek registration of a pipeline with a number of drug acquisition of Baxalta, including higher generic or biosimilar product and candidates in different therapeutic areas amortization of inventory fair value accordingly, are generally able to sell a under different phases of development.
adjustments and acquired intangible generic version of the Companys products For further details, see pages 20 to 21. assets, combined with higher integration at a much lower price.
2015: and acquisition costs, partially offset by As expected, in 2009, Teva and Impax lower impairment charges related to On February 21, 2015, Shire acquired commenced commercial shipments of their R&Dprograms.
NPS Pharma, which added global rights authorized generic versions of ADDERALL to an innovative product portfolio with Earnings per share EPS XR, which led to lower sales of branded multiple growth catalysts, including Diluted earnings per ADS decreased ADDERALL XR compared to the periods GATTEX REVESTIVE for the treatment 81percent to $1.27 2015: $6.59.
The prior to the authorized generic launches.
ofadults with SBS, a rare GI condition: decrease was primarily due to lower In 2014 and 2015, generic versions of the and NATPARA NATPAR, the only operating income resulting from the Companys INTUNIV product was bioengineered parathyroid hormone impact of the acquisition of Baxalta and launched, which led to lower sales of therapy for use in the treatment of HPT, higher integration and acquisition costs, INTUNIV product compared to the period arare endocrine disease.
combined with the impact of additional before loss of exclusivity.
shares issued as consideration for the On February 18, 2015, Shire acquired Baxalta transaction.
Shire is engaged in various legal Meritage Pharma, which provided the proceedings with generic manufacturers Company with worldwide rights to Cash flows with respect to its VYVANSE and LIALDA SHP621 for the potential treatment of Net cash provided by operating activities patents.
For information regarding current adolescents and adults with EoE, a rare, increased 14percent to $2,659 million patent litigation, see Note 26, Legal and chronic inflammatory GI disease.
2015: $2,337 million, primarily due to Other Proceedings, to the Consolidated strong cash receipts from higher sales, On July 30, 2015, Shire acquired Financial Statements.
partially offset by higher tax and interest Foresight, which added global rights to payments, costs related to the Baxalta SHP640, a Phase 3 ready potential Corporate Development integration and a payment associated therapy for the treatment of infectious Shire focuses its corporate development with the termination of a biosimilar conjunctivitis, an ocular surface condition activity on the acquisition and in-licensing collaboration acquired with Baxalta.
commonly referred to as pink eye.
of businesses, products or compounds Total revenues which offer a strategic fit and have the Results of operations for the The following table provides an analysis of potential to deliver demonstrable value to yearsended December 31, 2016 the Companys total revenues by source: allof the Companys stakeholders.
and 2015 Recent mergers and acquisitions As of 2016 2015 Change Financial highlights for the year ended 2016: December 31 $M $M % December 31, 2016 are as follows: Product sales 10,885.8 6,099.9 78 On January 22, 2016, Shire completed Revenues Royalties the acquisition of Dyax which expanded Product sales increased by 78percent andother and extended Shires industry-leading to$10,886 million 2015: $6,100 million.
revenues 510.8 316.8 61 HAE portfolio by adding the currently This increase was primarily due to Total 11,396.6 6,416.7 78 approved product, KALBITOR for the including $3,887 million of Baxalta treatment of sudden attacks of HAE in product sales following the acquisition, people 12 years of age and older and and double digit growth of existing SHP643, a Phase 3 program for the franchises, with Genetic Diseases up treatment of HAE.
12percent, Neuroscience up 13percent and Internal Medicine up 17percent.
In addition, the Company launched XIIDRA in August 2016 and the Ophthalmology franchise contributed sales of $54 million.
Shire Annual Report 2016 45 Other information Financial statements Governance Strategic report Review of our business continued Product sales Information about litigations related to VYVANSE can be found in Note 26, 2016 2015 Change Legaland Other Proceedings, to the As of December 31 $M $M % Consolidated Financial Statements.
Product sales: Immunology HEMOPHILIA 1,789.0 N A Immunology, acquired with Baxalta in INHIBITOR THERAPIES 451.8 N A June2016, reported product sales of Hematology total 2,240.8 N A $1,516 million.
Immunology includes CINRYZE 680.2 617.7 10.1 antibody-replacement immunoglobulin ELAPRASE 589.0 552.6 6.6 andbio therapeutics therapies.
FIRAZYR 578.5 445.0 30.0 Internal Medicine REPLAGAL 452.4 441.2 2.5 Internal Medicine product sales for the year VPRIV 345.7 342.4 1.0 ended December 31, 2016 increased to KALBITOR 52.2 N A $1,756 million or 17percent from $1,501 Genetic Diseases total 2,698.0 2,398.9 12.5 million in 2015, primarily driven by sales VYVANSE 2,013.9 1,722.2 16.9 growth from LIALDA MEZAVANT, GATTEX ADDERALL XR 363.8 362.8 0.3 REVESTIVE and NATPARA.
Other Neuroscience 112.8 115.4 2.2 LIALDA MEZAVANT product sales Neuroscience total 2,490.5 2,200.4 13.2 increased to $792 million or 16percent for IMMUNOGLOBULIN THERAPIES 1,143.9 N A the year ended December 31, 2016 from BIO THERAPEUTICS 372.2 N A $684 million in 2015, primarily due to an Immunology total 1,516.1 N A increase in prescription demand, resulting LIALDA MEZAVANT 792.1 684.4 15.7 in a U. S. market share of 40percent at the end of 2016 compared to 36percent PENTASA 309.4 305.8 1.2 in2015.
GATTEX REVESTIVE 219.4 141.7 54.8 NATPARA 85.3 24.4 249.6 Information about litigations related to Other Internal Medicine 349.3 344.3 1.4 LIALDA can be found in Note 26, Legal and Internal Medicine total 1,755.5 1,500.6 17.0 Other Proceedings, to the Consolidated Financial Statements.
Oncology total 130.5 N A Ophthalmology total 54.4 N A GATTEX REVESTIVE and NATPARA Total Product sales 10,885.8 6,099.9 78.5 product sales increased to $219 million or 55percent and $85 million or 250percent, respectively, for 2016, compared to product utilization as a result of a U. S. supply Hematology sales in 2015 primarily due to an increase in constraint during the second half of the Hematology, acquired with BaxaltaJune the numbers of patients on therapy.
Shire continues to execute on plans to 2016, includes sales of recombinant and increase CINRYZE production to meet both plasma-derived hemophilia products Oncology short-term and long-term patient demand.
primarily factor VIII and factor IX and Oncology, acquired with Baxalta in inhibitor therapies.
Product sales of the June2016, reported product sales of Neuroscience franchise for the year ended December 31, $131million.
Oncology includes sales of Neuroscience product sales for the year 2016 were $2,241million.
ONIVYDE was ended December 31, 2016 increased to approved in the EU on October 18, 2016.
Genetic Diseases $2,490 million or 13percent from $2,200 Genetic Diseases product sales for the year million in 2015, primarily driven by sales Ophthalmology ended December 31, 2016 increased to growth of VYVANSE.
Ophthalmology product sales relate to $2,698 million or 12percent from $2,399 XIIDRA, which was made available to VYVANSE sales for the year ended million in 2015, primarily driven by patients on August 29, 2016.
XIIDRA December 31, 2016 increased to increased demand for HAE therapies.
product sales were $54 million for the $2,014million or 17percent from yearended December 31, 2016.
FIRAZYR product sales for the year ended $1,722million in 2015, due to prescription December 31, 2016 increased to $579 growth in the U. S. adult market, which million or 30percent from $445 million in includes ADHD and BED, and the benefit 2015, primarily due to an increase in the ofprice increases taken since 2015 number of patients on therapy in both the andgrowth in the Companys U. S. and international markets.
sales for the year ended December 31, 2016 increased to $680 million or 10percent from $618 million in 2015, as anincrease in the number of patients on therapy was partially offset by reduced 46 Shire Annual Report 2016 In 2015, Shire recorded net integration Royalties and other revenues R&D andacquisition costs of $40 million, R&D expense decreased by $124 million, As of 2016 2015 Change representing acquisition and integration or8percent, to $1,440 million for the year December 31 $M $M % costs of $190 million, primarily related to ended December 31, 2016 13percent of SENSIPAR NPS, ViroPharma, Baxalta and Dyax.
Product sales from $1,564 million in 2015 royalties 151.5 114.5 32 These costs were offset by a net credit of 26percent of Product sales, as lower 3TC and ZEFFIX $150 million from the change in fair value of IPR&D impairment charges in 2016 more royalties 58.9 49.1 20 contingent consideration, primarily relating than offset the increase in costs related to FOSRENOL to SHP625 and SHP608.
Baxalta and Dyax and costs related to royalties 48.2 46.1 5 licensing SHP647.
R&D expense in Reorganization costs ADDERALL XR 2015included impairment charges of For the year ended December 31, 2016, royalties 32.3 26.0 24 $467million related to the SHP625 IPR&D Shire recorded reorganization costs of Other royalties intangible asset, due to a lower probability $121million primarily related to the planned and revenues 219.9 81.1 171 of regulatory approval following trial results closure of a facility at the Los Angeles and revised commercial potential, and Total 510.8 316.8 61 manufacturing site acquired with Baxalta $177million related to the SHP608 IPR&D inJune 2016. intangible asset, following preclinical toxicity Royalties and other revenues increased findings.
No significant impairment charges to$511 million or 61percent for the year Reorganization costs of $98 million for the occurred in 2016. ended December 31, 2016 from year ended December 31, 2015, primarily $317million in 2015, primarily due to related to the relocation of roles from R&D expense for the year ended $99million of contract manufacturing Pennsylvania to Massachusetts.
December31, 2016 included depreciation revenue from the acquisition of Baxalta.
Interest Expense Cost of product sales Other expense, net increased by SG&A Cost of product sales increased by $443million to $477 million for the year SG&A expense increased by $1,173 million, $2,848million to $3,817 million for the year ended December 31, 2016 from $34million or 64percent, to $3,015 million for the year ended December 31, 2016 35percent of in 2015, primarily due to higher interest ended December 31, 2016 28percent of Product sales from $969 million in 2015 expense and amortization of one-time Product sales from $1,843 million in 2015 16percent of Product sales primarily due borrowing costs, including the write off of 30percent of Product sales, primarily due to the impact of higher amortization of certain financing costs related to the bridge to the inclusion of Baxalta related costs and inventory fair value adjustments in 2016 facility for the Baxalta transaction.
During XIIDRA launch and promotional costs.
following the acquisitions of Baxalta and the third quarter of 2016, the bridge facility Dyax and, to a lesser extent, the impact of was fully repaid with the proceeds from the For the year ended December 31, 2016, lower margin product franchises acquired $12.1 billion public debt offering.
SG&A expense included depreciation of with Baxalta.
Cost of product sales $98 million 2015: $71 million.
Taxation included $1,118 million and $31 million of Amortization of acquired intangible The effective tax rate on income from amortization of inventory fair value assets continuing operations for the year ended adjustments in 2016 and 2015, respectively.
For the year ended December 31, 2016, December 31, 2016 was a benefit of For the year ended December 31, 2016, Shire recorded Amortization of acquired 26percent 2015: charge of 3percent.
The Cost of product sales included additional intangible assets of $1,173 million effective tax rate on income from continuing depreciation totaling $161 million 2015: compared to $499 million in 2015.
The operations in 2016 was lower primarily due $46 million, primarily due to the acquisition increase of $675 million was primarily to the combined impact of the relative of Baxalta.
related to amortization on the intangible quantum of the profit before tax for the assets acquired with the Baxalta and Dyax period by jurisdiction and the reversal of transactions.
deferred tax liabilities including in higher tax territories from the Baxalta acquisition, Integration and acquisition costs inventory and intangible asset amortization, For the year ended December 31, 2016, as well as acquisition and integration costs.
Shire recorded integration and acquisition costs of $884 million, primarily related to the Baxalta and Dyax transactions, which included severance and employee termination benefits and office closure related expenses.
Shire Annual Report 2016 47 Other information Financial statements Governance Strategic report Review of our business continued Discontinued operations generated from sales of Shires products In addition, in connection with the The loss from discontinued operations for and royalty receipts.
acquisition of Baxalta, on June 3, 2016, the year ended December 31, 2016 was Shire plc guaranteed senior notes issued An important part of Shires business $276 million, net of tax benefit of $99 by Baxalta with a total aggregate principal strategy is to protect its products and million, primarily related to legal amount of $5 billion and assumed technologies through the use of patents, contingencies for the divested $336million of capital lease obligations.
proprietary technologies and trademarks, DERMAGRAFT business.
The loss from The details of these senior notes are to the extent available.
The Company discontinued operations for the year ended presented in Note 18, Borrowings and intends to defend its intellectual property December 31, 2015 was $34 million, net Capital Lease Obligations, to the and as a result may need cash for funding oftax, primarily related to a change in Consolidated Financial Statements.
estimate for abandoned facilities charges.
Further in connection with the acquisitions The Company finances its activities through of Dyax and Baxalta, respectively, Shire Liquidity and Capital Resources cash generated from operating activities: entered into a $5.6 billion amortizing term General credit facilities: private and public offerings loan facility in November 2015 and an The Companys funding requirements of equity and debt securities: and the $18billion bridge loan in January 2016. depend on a number of factors, including proceeds of asset or investment disposals.
TheNovember 2015 term loan facility was the timing and extent of its development fully utilized as of December 31, 2016 in programs: corporate, business and product Shires Consolidated Balance Sheets theamount of $5 billion.
The bridge loan acquisitions: the level of resources required included $529 million of Cash and cash was fully repaid and canceled subsequent for the expansion of certain manufacturing equivalents as of December 31, 2016. to the issuance of $12.1 billion in senior and marketing capabilities as the product Shire has a revolving credit facility RCF notes on September 23, 2016.
The details base expands: increases in accounts of $2,100 million which matures in 2021, of these facility agreements are presented receivable and inventory which may arise $450 million of which was utilized as of in Note 18, Borrowings and Capital Lease with any increase in Product sales: December 31, 2016.
The RCF incorporates Obligations, to the Consolidated competitive and technological developments: a $250 million U. S. Dollar and Euro FinancialStatements.
the timing and cost of obtaining required swingline facility operating as a sub-limit regulatory approvals for new products: the In addition, Shire also has access to certain thereof.
timing and quantum of milestone payments short-term uncommitted lines of credit which on business combinations, in-licenses and On September 23, 2016, Shire Acquisitions are available to utilize from time to time to collaborative projects: the timing and Investments Ireland Designated Activity provide short-term cash management quantum of tax and dividend payments: Company SAIIDAC, a wholly owned flexibility.
As of December 31, 2016, these thetiming and quantum of purchases by subsidiary of the Company, issued senior lines of credit were not utilized.
the Employee Benefit Trust EBT of notes guaranteed by Shire plc with a total Shireshares in the market to satisfy The Company may also engage in financing aggregate principal amount of $12.1 billion.
awardsgranted under Shires employee activities from time to time, including On December 1, 2016, Baxalta guaranteed share plans: and the amount of cash accessing the debt or equity capital markets.
the outstanding notes issued by SAIIDAC.
Senior Notes Issuance On September 23, 2016, SAIIDAC, issued senior notes with a total aggregate principal value of $12.1 billion SAIIDAC Notes, guaranteed by Shire plc and, as of December 1, 2016, by Baxalta.
SAIIDAC used the net proceeds to fully repay amounts outstanding under the January 2016 Facilities Agreement discussed below, which was used to finance the cashconsideration payable related to the Companys acquisition of Baxalta.
Below isa summary of the SAIIDAC Notes as of December 31, 2016: Aggregate Coupon Effective Carrying amount rate interest rate amount $M % % $M Fixed-rate notes due 2019 3,300.0 1.900 2.05 3,287.5 Fixed-rate notes due 2021 3,300.0 2.400 2.53 3,283.0 Fixed-rate notes due 2023 2,500.0 2.875 2.97 2,487.9 Fixed-rate notes due 2026 3,000.0 3.200 3.30 2,980.8 12,100.0 12,039.2 The SAIIDAC Notes are senior unsecured obligations and may be redeemed at SAIIDACs option at the greater of 1 100percent of the principal amount plus accrued and unpaid interest or 2 the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the applicable treasury rate as defined plus an incremental margin, plus, in either case, accrued and unpaid interest.
The SAIIDAC Notes also contain a change of control provision that may require that SAIIDAC to offer to purchase the SAIIDAC Notes at a price equal to 101percent of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.
The costs and discount associated with this offering of $61 million have been recorded as a reduction to the carrying amount of the debt on the Consolidated Balance Sheets.
These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity.
Interest on the SAIIDAC Notes is payable March 23 and September 23 of each year, beginning on March 23, 2017.
48 Shire Annual Report 2016 Baxalta Notes Shire plc guaranteed senior notes issued by Baxalta with a total aggregate principal amount of $5 billion in connection with the Baxalta acquisition Baxalta Notes.
Below is a summary of the Baxalta Notes as of December 31, 2016: Aggregate Coupon Effective Carrying principal rate interest rate amount $M % % $M LIBOR plus Variable-rate notes due 2018 375.0 0.780 2.20 371.6 Fixed-rate notes due 2018 375.0 2.000 2.00 374.8 Fixed-rate notes due 2020 1,000.0 2.875 2.80 1,004.3 Fixed-rate notes due 2022 500.0 3.600 3.30 508.4 Fixed-rate notes due 2025 1,750.0 4.000 3.90 1,772.8 Fixed-rate notes due 2045 1,000.0 5.250 5.10 1,031.7 Total Baxalta Notes 5,000.0 5,063.6 The effective interest rates above exclude the effect of any related interest rate swaps.
The book values above include any premiums andadjustments related to hedging instruments.
For further details related to the interest rate derivative contracts, please see Note 16, Financial Instruments, to the Consolidated Financial Statements.
connection with the period ending June 30, Shire shall also pay i a commitment fee Revolving Credit Facilities 2016, following the completion of the equal to 35percent of the applicable Agreement acquisition of Baxalta during the period.
margin on available commitments under On December 12, 2014, Shire entered into Consequently, the applicable ratio for the the RCF for the availability period applicable a $2,100 million revolving credit facilities period ending December 31, 2016 is 5.0:1. thereto and ii a utilization fee equal to agreement the RCF with a number of a 0.10percent per year of the aggregate financial institutions.
Shire is an original The RCF restricts, subject to certain ofall outstanding loans up to an aggregate borrower and original guarantor under the exceptions, Shires ability to incur additional base currency amount equal to RCF.
On January 15, 2016, SAIIDAC financial indebtedness, grant security over $700million, b 0.15percent per year of became additional guarantor to the RCF its assets or provide loans grant credit.
theamount by which the aggregate base and on December 1, 2016, Baxalta became Further, any lender may require mandatory currency amount of all outstanding loans additional guarantor to the RCF.
Shire has prepayment of its participation if there is exceeds $700 million but is equal to or less agreed to act as guarantor for any of its achange of control of Shire, subject to than $1,400 million and c 0.30percent per subsidiaries that become additional certain exceptions for schemes of year of the amount by which the aggregate borrowers under the RCF.
As of December arrangement and analogous schemes.
base currency amount of all outstanding 31, 2016 the Company utilized $450 million loans exceeds $1,400 million.
Events of default under the RCF include, of the RCF.
subject to customary grace periods and The RCF includes customary representations The RCF, which terminates on December materiality thresholds: i non-payment of and warranties, covenants and events of 12, 2021, may be applied towards financing any amounts due under the finance default, including requirements that Shires the general corporate purposes of Shire.
documents as defined in the RCF, i ratio of Net Debt to EBITDA in respect of The RCF incorporates a $250 million U. S. ii failure to satisfy any financial covenants, the most recently-ended 12-month relevant Dollar and Euro swingline facility operating iii material misrepresentation in any of the period each as defined in the RCF must as a sub-limit thereof.
finance documents, iv failure to pay, or not, at any time, exceed 3.5:1 except that, certain other defaults, under other financial Interest on any loans made under the RCF following an acquisition fulfilling certain indebtedness, v certain insolvency events is payable on the last day of each interest criteria, Shire may elect to increase this or proceedings, vi material adverse period, which may be one week or one, ratio to a 5.5:1 for the relevant period in changes in the business, operations, two, three or six months at the election of which the acquisition was completed assets or financial condition of Shire as a Shire, or as otherwise agreed with the b 5.0:1 in respect of the first relevant whole, vii if it becomes unlawful for Shire lenders.
The interest rate for the RCF is: period following the relevant period in or any successor parent company or any LIBOR or, in relation to any revolving loan which the acquisition was completed and of their respective subsidiaries that are inEuro, EURIBOR : plus 0.30percent per c 4.5:1 inrespect of the second relevant parties to the RCF to perform their annum subject to change depending upon period following the relevant period in obligations thereunder or viii if Shire or i the prevailing ratio of Net Debt to EBITDA which the acquisition was completed and any successor parent company or any each as defined in the RCF in respect of ii ratio ofEBITDA to Net Interest for the subsidiary thereof which is a party to the the most recently completed financial year most recently-ended 12-month relevant RCF repudiates such agreement or other or financial half year and ii the occurrence period each as defined in the RCF must finance document, among others.
and continuation of an event of default in not be less than 4.0:1.
Shire elected to respect of the financial covenants or the increase the Net Debt to EBITDA ratio in failure to provide a compliance certificate.
Shire Annual Report 2016 49 Other information Financial statements Governance Strategic report Review of our business continued SAIIDAC made its first repayment or provide loans grant credit.
Further, any Term Loan Facilities Agreement installment of $400.0 million of the lender may require mandatory prepayment January 2016 Facilities Agreement November 2015 Facility B in accordance of its participation if there is a change of On January 11, 2016, Shire as original with the terms of the agreement.
control of Shire, subject to certain guarantor and original borrower, entered exceptions for schemes of arrangement into an $18 billion bridge facilities Interest on any loans made under the and analogous schemes.
agreement with various financial institutions November 2015 Facilities Agreement is the January 2016 Facilities Agreement.
payable on the last day of each interest Events of default under the November 2015 The January 2016 Facilities Agreement period, which may be one week or one, Facilities Agreement include, subject to comprised two credit facilities: i a $13billion two, three or six months, or as otherwise customary grace periods and materiality term loan facility originally maturing on agreed with the lenders.
The interest rate thresholds: i non-payment of any amounts January 11, 2017 January 2016 Facility A applicable is LIBOR plus, in the case of the due under the finance documents as and ii a $5 billion revolving loan facility November 2015 Facility A, 0.55percent per defined in the November 2015 Facilities originally maturing on January 11, 2017 annum, in the case of the November 2015 Agreement, ii failure to satisfy any financial January 2016 Facility B.
On April 1, 2016 Facility B, 0.65percent per annum and, in covenants, iii material misrepresentation SAIIDAC became additional borrower and the case of the November 2015 Facility C, inany of the finance documents, iv failure additional guarantor to the January 2016 0.75percent per annum, in each case to pay, or certain other defaults, under other Facilities Agreement.
subject to change depending on i the financial indebtedness, v certain insolvency prevailing ratio of Net Debt to EBITDA events or proceedings, vi material adverse The January 2016 Facility A was utilized to eachas defined in the November 2015 changes in the business, operations, finance the cash consideration payable in Facilities Agreement inrespect of the assets or financial condition of Shire as a respect of the acquisition of Baxalta on mostrecently completed financial year or whole, vii if it becomes unlawful for Shire June 3, 2016 in the amount of $12,390 financial half year and ii the occurrence or any successor parent company or any million.
The net proceeds from the issuance and continuation of an event of default in of their respective subsidiaries that are of the SAIIDAC Notes were used to fully respect of the financial covenants or failure parties to the November 2015 Facilities repay the amounts outstanding under the to provide a compliance certificate.
Agreement toperform their obligations January 2016 Facility A in September 2016. thereunder or viii if Shire or any successor The January 2016 Facility B was canceled The November 2015 Facilities Agreement parent company or any subsidiary thereof effective July 11, 2016, in accordance with includes customary representations and which is a party tothe November 2015 its terms.
warranties, covenants and events of Facilities Agreement repudiates the default, including requirements that Shires November 2015 Facilities Agreement November 2015 Facilities Agreement or any i ratio of Net Debt to EBITDA in respect of On November 2, 2015, Shire as original other finance document, among others.
the most recently ended 12-month relevant guarantor and original borrower entered period, each as defined in the November January 2015 Facility Agreement into a $5.6 billion facilities agreement with 2015 Facilities Agreement, must not, at any On January 11, 2015, Shire entered into an various financial institutions the November time, exceed 3.5:1, except that following an $850.0 million term facility agreement with 2015 Facilities Agreement.
The November acquisition fulfilling certain criteria, Shire various financial institutions the January 2015 Facilities Agreement comprises three may elect to increase this ratio to 2015 Facility Agreement with an original credit facilities: i a $1.0 billion term loan a 5.5:1for the relevant period in which maturity date of January 10, 2016.
The facility of which, following the exercise of theacquisition was completed, b 5.0:1 in maturity date was subsequently extended the one year extension option in the respect of the first relevant period following to July 11, 2016 in line with the provisions amount of $400.0 million, $600.0 million the relevant period in which the acquisition within the January 2015 Facility Agreement matured and was repaid on November 2, was completed, Shire has elected to allowing the maturity date to be extended 2016 and $400.0 million matures on increase this ratio in connection with the twice, at Shires option, by six months on November 2, 2017 November 2015 period ended June 30, 2016, following the each occasion.
Facility A, ii a $2.2 billion amortizing term completion of the acquisition of Baxalta loan facility which matures on November 2, The January 2015 Facility Agreement was during the period and c 4.5:1 in respect 2017 November 2015 Facility B and used to finance Shires acquisition of NPS ofthe second relevant period following the iii a$2.4 billion amortizing term loan facility Pharma including certain related costs.
relevant period in which the acquisition which matures on November 2, 2018 OnSeptember 28, 2015, the Company wascompleted, Shire has elected to November 2015 Facility C. reduced the January 2015 Facility increase this ratio in connection with the Agreement by $100.0 million.
In January On January 15, 2016, SAIIDAC became period ending June 30, 2016, following 2016 and at various points thereafter, additional borrower and additional thecompletion of the acquisition of Baxalta theCompany canceled parts of the guarantor to the November 2015 Facilities during the period and ii ratio of EBITDA to January 2015 Facility Agreement.
On Agreement and on December 1, 2016, Net Interest in respect of the most recently February 22, 2016, the Company repaid the Baxalta became an additional guarantor to ended 12-month relevant period, each as remaining balance of $100.0 million of the the November 2015 Facilities Agreement.
defined in the November 2015 Facilities January 2015 Facilities Agreement in full.
As of December 31, 2016, the November Agreement, must not be less than 4.0:1.
2015 Facilities Agreement was fully utilized The November 2015 Facilities Agreement by SAIIDAC as borrower in the amount of restricts, subject to certain exceptions, $5.0 billion to finance the cash consideration Shires ability to incur additional financial payable and certain costs related to the indebtedness, grant security over its assets acquisition of Dyax.
On January 30, 2017, 50 Shire Annual Report 2016 Short-term uncommitted lines of credit Substantially all of the Companys cash Net cash used in investing activities was Credit lines and cash equivalents are held by foreign $18,092.2 million for the year ended Shire has access to various Credit lines from subsidiaries i. e. those subsidiaries December 31, 2016, primarily related to the a number of banks which are available to be incorporated outside of Jersey, Channel cash paid for the acquisitions of Baxalta utilized from time to time to provide shortIslands, the jurisdiction of Shire plcs $12,367 million, less cash acquired of term cash management flexibility.
The amount of cash $583million and Dyax $5,934 million, Credit lines can be withdrawn by the banks andcash equivalents held by foreign lesscash acquired of $241 million.
The Credit lines are not relied subsidiaries has not had, and is not TheCompanys investing activities also upon for core liquidity.
As of December 31, expected to have, a material impact includedthe purchase of $649 million 2016, these Credit lines were not utilized.
onthe Companys liquidity and ofPP&E due to the continued investment capitalresources.
Financing Net debt cash is a Non GAAP measure.
Net cash used in investing activities was Shire anticipates that its operating cash The Company believes that Net debt $5,619.9 million for the year ended flow together with available cash, cash cash is a useful measure as it indicates December 31, 2015, primarily related to equivalents, and the RCF will be sufficient the level of net cash borrowings after thecash paid for the acquisition of NPS to meet its anticipated future operating taking account of the Cash and cash Pharma of $5,220 million excluding cash expenses, capital expenditures, tax and equivalents that could be utilized to pay acquired with NPS Pharma of $42 million interest payments, lease obligations, down the outstanding borrowings.
See and for the acquisitions of Foresight $299 repayment of the term loans and milestone above for reconciliation to cash and million and Meritage Pharma $75 million.
payments as they become due over the cashequivalents.
Net cash provided by financing activities Cash flow activity was $15,825.8 million for the year ended If the Company decides to acquire other Net cash provided by operating activities December 31, 2016, principally due to the businesses, it expects to fund these for the year ended December 31, 2016 issuance of the SAIIDAC Notes in addition to acquisitions from cash resources, the RCF increased 14percent to $2,658.9 million the drawings, net of subsequent repayments, and through new borrowings including 2015: $2,337.0 million, primarily due to made under various other borrowing issuances of debt securities or the increased cash receipts from higher sales, facilities to partially fund the acquisitions of issuance of new equity, if necessary.
partially offset by higher tax and interest Baxalta and Dyax.
In addition, the Company Sources and uses of cash payments, costs related to the Baxalta made dividend payments of $171.3 million.
The following table provides an analysis integration and a payment associated with Net cash provided by financing activities ofthe Companys gross and net cash the termination of a biosimilar collaboration was $439.0 million for the year ended excluding restricted cash, as of acquired with Baxalta.
December 31, 2015, principally due to the December31, 2016 and 2015: Net cash provided by operating activities drawings, net of subsequent repayments, 2016 2015 for the year ended December 31, 2015 made under Shires various borrowing As of December 31 $M $M decreased by 45percent to $2,337.0 million facilities to partially fund the NPS Pharma, 2014: $4,228.4 million.
Net cash provided Meritage Pharma and Foresight Cash and cash by operating activities in 2014 included the equivalents 528.8 135.5 acquisitions.
In addition, the Company receipt of the $1,635 million break fee made dividend payments of $134.4 million.
Long-term related to AbbVies terminated offer for borrowings 19,552.6 69.9 Outstanding Letters of credit Shire, and the benefit of the $417 million Short-term As of December 31, 2016, the Company repayment received from the Canadian borrowings 3,061.6 1,511.5 had irrevocable standby letters of credit revenue authorities.
The net cash flows Other debt 353.6 13.4 and guarantees with various banks totaling from operating activities was also Total debt 22,967.8 1,594.8 $139.7 million, providing security for the impactedby an increase of $160.6 million Companys performance of various Net debt 22,439.0 1,459.3 as a result of higher cash receipts from obligations.
These obligations are gross product sales and royalties, which primarilyin respect of the recoverability of were partially offset by higher operating insurance claims, lease obligations and expense payments.
Cash Requirements As of December 31, 2016, the Companys cash requirements for current and non-current liabilities reflected on the Consolidated Balance Sheets and other contractual obligations were as follows: Less than More than Total 1 year 1-3 years 3-5 years 5 years $M $M $M $M $M Borrowings and capital lease obligations 27,452.0 3,072.6 6,569.5 4,456.8 13,353.1 Operating leases obligations 985.2 155.5 215.9 171.9 441.9 Purchase obligations 3,488.6 1,092.7 1,398.4 799.0 198.5 Other non-current liabilities 587.9 452.7 42.0 93.2 Total 32,513.7 4,320.8 8,636.5 5,469.7 14,086.7 Shire Annual Report 2016 51 Other information Financial statements Governance Strategic report Review of our business continued Milestone payments related with Borrowings and capital lease obligations Treasury policies and organization collaboration agreements that become include interest payments related to the The Companys principal treasury payable only if the Company chooses to fixed-rate borrowings.
operations are coordinated by its corporate exercise one or more of its options and treasury function.
All treasury operations The Company leases certain land, potential contingent payments are conducted within a framework of facilities, motor vehicles and certain associated with R&D costs that may policies and procedures approved annually equipment under operating leases befunded by collaboration partners by the Board of Directors.
As a matter of expiring through 2021. inthe future.
policy, the Company does not undertake speculative transactions that would Purchase obligations include agreements An unfunded commitment of $76.4 increase its credit, currency or interest to purchase goods, investments or million as a limited partner in multiple rateexposure.
services including clinical trials, contract investment companies, in which the manufacturing and capital equipment, timing of future payments is uncertain.
Interest rate risk and open purchase orders, that are The Company is exposed to the risk that its enforceable and legally binding and Off-balance sheet arrangements earnings and cash flows could be adversely thatspecify all significant terms.
Shire There are no off-balance sheet impacted by fluctuations in benchmark expects to fund these commitments arrangements, aside from those outlined interest rates relating to its debt obligations withcash flows from operating activities.
above, that have, or are reasonably likely on which interest is set at floating rates.
tohave, a current or future material effect TheCompanys policy is to manage this Unrecognized tax benefits and on the Companys financial condition, risk to an acceptable level.
The Company associated interest and penalties of revenues or expenses, results of isprincipally exposed to interest rate risk $201.1 million are included within operations, liquidity, capital expenditures onany borrowings under the Companys payments due in one to three years.
various debt facilities and on part of the The following items have been excluded senior notes assumed in connection with Foreign currency fluctuations from the table above: the acquisition of Baxalta.
Interest on each A number of the Companys subsidiaries of these debt obligations is set at floating have a functional currency other than the Cash outflows related to the assumed rates, to the extent utilized.
As such, the consolidated pension and other post-employment exposure under these facilities is to financial results are subject to fluctuations benefit plans, in which timing of funding changes in U. S. Dollar interest rates.
For in exchange rates, particularly in the Euro, is uncertain and dependent on future details see Note 16, Financial Instruments, Swiss Franc, Japanese Yen and Pound movements in interest rates and to the Consolidated Financial Statements.
Sterling against the U. S. Dollar.
investment returns, changes in laws and regulations and other variables.
The Company is also exposed to interest Accumulated foreign currency translation rate risk on its restricted cash, cash and differences of $1,505.4 million are reported In connection with the Companys cash equivalents and on foreign exchange within Accumulated other comprehensive acquisitions, the Company recorded contracts on which interest is set at floating income as of December 31, 2016.
Foreign contingent consideration liabilities related rates.
As the Company maintains all of its gains for the year ended December 31, to development, regulatory and cash, liquid investments and foreign 2016 of $17.7 million are reported in the commercial milestones and royalty exchange contracts on a short-term basis Consolidated Statements ofOperations.
These liabilities were recorded for liquidity purposes, this risk is not actively at fair value on the respective acquisition As of December 31, 2016, the Company managed.
For the year ended December dates and revalued each reporting had outstanding foreign exchange swap 31, 2016, the average interest rate received period.
The Company may pay up to and forward contracts that manage the on cash and liquid investments was less approximately $2.0 billion, which currency risk associated with intercompany than 1percent per annum.
These cash and excludes royalty related payments, transactions.
As of December 31, 2016 the liquid investments were primarily invested uponachieving clinical, regulatory and fair value of these contracts was anet asset inU.
S. Dollar term deposits with banks and commercialization milestones.
money market and liquidity funds or held additional information, see Note 15, ascash on account.
Although at reduced levels in recent As of December 31, 2016, Shire estimates Milestone payments to third-parties years, inflation continues to apply upward that a hypothetical increase and decrease uponthe achievement of development, pressure on the cost of goods and services of 100 basis points in interest rates would regulatory and commercial milestones, which are used in the business.
However, increase and decrease net interest costs as well as potential royalty payments, the Company believes that the net effect of byapproximately $60.0 million and $50.0 associated with in-licensing and inflation on its revenues and operations has million respectively during 2017, and collaboration agreements.
Potential been minimal during the past three years.
decrease and increase the fair value of future milestone payments associated long-term interest rate sensitive instruments with collaborations was approximately by approximately $970.0 million and $1.7 billion, which excludes potential $1,061.0 million, respectively, during the royalty payments.
52 Shire Annual Report 2016 Foreign exchange risk As of December 31, 2016 the Company A substantial portion of the Companys The Company operates in numerous had designated and undesignated foreign accounts receivable in countries outside countries and as a consequence has exchange forward contracts.
For more ofthe U. S. is derived from Product sales foreign exchange exposure.
The main detail of foreign exchange forward togovernment-owned or governmentoperating currencies of the Company are contracts, see Note 16, Financial supported healthcare providers.
The the U. S. Dollar, Pounds Sterling, Swiss Instruments, to the Consolidated Companys recovery of these accounts Franc, Canadian Dollar, Japanese Yen and FinancialStatements.
receivable is therefore dependent upon the the Euro.
It is the Companys policy that financial stability and creditworthiness of Concentration of credit risk these exposures are minimized to the the relevant governments.
In recent years Financial instruments that potentially extent practicable by denominating global and national economic conditions expose Shire to concentrations of credit transactions inthe subsidiarys functional have negatively affected the growth, risk consist primarily of short-term cash currency.
creditworthiness and general economic investments, derivative contracts and trade condition of certain markets in which the Where significant exposures remain, the accounts receivable from Product sales Company operates.
As a result, in some Company uses foreign exchange contracts and from third-parties from which the countries outside of the U. S. specifically, spot, forward and swap contracts to Company receives royalties.
Cash is Argentina, Brazil, Greece, Italy, Portugal manage the exposure for balance sheet invested in short-term money market and Spain, the Company is experiencing assets and liabilities that are denominated instruments, including money market and delays in the remittance of receivables due in currencies different to the functional liquidity funds and bank term deposits or from government-owned or governmentcurrency of the relevant subsidiary.
The money market and supported healthcare providers.
Of those, assets and liabilities relate predominantly to liquidity funds where Shire invests are all the only significant accounts receivable as inter-company financing.
The Company has triple A rated by both Standard and Poors of December 31, 2016 is $140.2 million not elected hedge accounting for these and by Moodys credit rating agencies.
Cash flows from derivative The Company is exposed to the credit risk instruments are presented within net cash The Company will continue to evaluate of the counterparties with which it enters provided by operating activities in the allits accounts receivable for potential into bank term deposit arrangements and Consolidated Statements of Cash Flows, collection risks and has made provision for derivative instruments.
The Company limits unless the derivative instruments are amounts where collection is considered to this exposure through a system of internal economically hedging specific investing or be doubtful.
Any such loss could have an credit limits which vary according to ratings financing activities.
adverse effect on the Companys financial assigned to the counterparties by the major condition and results of operations.
The Translational foreign exchange exposure rating agencies.
The internal credit limits Company does not consider it is currently arises on the translation into U. S. Dollars of are approved by Shires Board of Directors exposed to significant credit risk outside the financial statements of non-U.
S. Dollar and exposure against these limits is ofthe countries listed above.
For details see monitored by the Companys corporate Note16, Financial Instruments, to the treasury function.
The counterparties to Consolidated Financial Statements.
these derivatives contracts are major international financial institutions.
Foreign exchange risk sensitivity The Companys revenues from Product The following exchange rate sensitivity sales in the U. S. are mainly governed by analysis summarizes the sensitivity of the agreements with major pharmaceutical Companys reported revenues and net wholesalers and relationships with other income to hypothetical changes in the pharmaceutical distributors and retail average annual exchange rates of the pharmacy chains.
For the year ended Euro, Pound Sterling and Swiss Franc December 31, 2016, there were three against the U. S. Dollar, assuming a customers in the U. S. that accounted for hypothetical 10percent strengthening 38percent of the Companys Product sales.
ofthe U. S. Dollar against each of the aforementioned currencies in the year Suchcustomers typically have significant ended December 31, 2016 : cash resources and as such the risk from concentration of credit is considered Reduction in Reduction in acceptable.
The Company has taken revenues net income $M $M positive steps to manage any credit risk associated with these transactions and Euro 153.2 64.6 operates clearly defined credit evaluation Pound Sterling 25.3 11.6 procedures.
However, an inability of one or Swiss Franc 5.8 1.4 more of these wholesalers to honor their debts to the Company could have an A 10percent weakening of the U. S. Dollar adverse effect on the Companys financial against the aforementioned currencies condition and results of operations.
would have an equal and opposite effect.
Shire Annual Report 2016 53 Other information Financial statements Governance Strategic report
